Wedbush Increases Earnings Estimates for Vera Therapeutics

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities research analysts at Wedbush boosted their Q1 2025 earnings estimates for shares of Vera Therapeutics in a research report issued on Thursday, February 27th. Wedbush analyst L. Chico now anticipates that the company will post earnings of ($0.72) per share for the quarter, up from their previous forecast of ($0.81). Wedbush currently has a "Neutral" rating and a $38.00 target price on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics' Q2 2025 earnings at ($0.73) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.20) EPS, FY2026 earnings at ($3.58) EPS, FY2027 earnings at ($2.08) EPS and FY2028 earnings at $0.20 EPS.

A number of other equities research analysts have also recently issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an "overweight" rating in a report on Tuesday, November 5th. Wells Fargo & Company assumed coverage on shares of Vera Therapeutics in a report on Thursday, November 21st. They set an "overweight" rating and a $70.00 price target for the company. The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $58.00 price target for the company. Wolfe Research assumed coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price objective for the company. Finally, Guggenheim upped their price objective on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $65.11.

Vera Therapeutics Stock Down 5.1 %

NASDAQ:VERA traded down $1.52 during trading hours on Monday, reaching $28.41. The company's stock had a trading volume of 789,778 shares, compared to its average volume of 905,249. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics has a one year low of $25.99 and a one year high of $51.61. The business's 50-day moving average is $35.75 and its 200-day moving average is $40.35. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -10.89 and a beta of 1.11.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11.

Insider Buying and Selling

In other news, CEO Marshall Fordyce sold 17,500 shares of the firm's stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total transaction of $730,450.00. Following the completion of the sale, the chief executive officer now owns 143,603 shares of the company's stock, valued at approximately $5,993,989.22. This trade represents a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold 52,500 shares of company stock valued at $2,305,625 over the last quarter. Corporate insiders own 21.70% of the company's stock.

Institutional Trading of Vera Therapeutics

Several hedge funds have recently modified their holdings of the company. Huntington National Bank bought a new stake in shares of Vera Therapeutics during the fourth quarter valued at approximately $26,000. AlphaQuest LLC bought a new position in Vera Therapeutics in the fourth quarter valued at approximately $34,000. GF Fund Management CO. LTD. bought a new position in Vera Therapeutics in the fourth quarter valued at approximately $56,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Vera Therapeutics by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company's stock worth $86,000 after purchasing an additional 350 shares during the period. Finally, KBC Group NV raised its holdings in Vera Therapeutics by 127.2% in the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after purchasing an additional 1,387 shares during the period. Institutional investors and hedge funds own 99.21% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.